<DOC>
	<DOC>NCT00621881</DOC>
	<brief_summary>This is an open-label study that will compare the pharmacokinetic and safety effects of naproxcinod in hepatic impaired patients vs. matching healthy subjects.</brief_summary>
	<brief_title>A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects</brief_title>
	<detailed_description>This is an open-label, non-randomized, parallel-group study that will be conducted at two study sites. Patients with hepatic impairment and matched healthy subjects will receive naproxcinod 750 mg bid for 6 days and qd for the last day.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Male or Female, age 40 to 75 years with stable hepatic insufficiency conforming to ChildPugh classification B OR Male or Female, age 40 to 75 years with similar distribution of age, weight, gender, smoking habits, and race, and in general good health Current or expected use of anticoagulants or analgesic, antiinflammatory therapies except lose dose aspirin History of renal impairment Diagnosis of gastric or duodenal ulceration and/or history of significant gastroduodenal bleeding within the last 6 months Clinically relevant abnormal ECG Alcohol or drug abuse within the last 6 months Any significant or chronic disease (except hepatic insufficiency for the patient cohort) which may interfere with study evaluations</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hepatic impairment</keyword>
</DOC>